Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental

L O Somova1, A Nadar, P Rammanan

  • 1Department of Human Physiology, University of Durban-Westville, Durban, South Africa. somova@pixie.udw.ac.za

Insights

Oleanolic acid (OA) and ursolic acid (UA) prevented severe hypertension in rats by acting as diuretics and antioxidants. These triterpenoids also reduced heart rate, lipids, and blood glucose levels.

Area of Science:

  • Pharmacology and Toxicology
  • Cardiovascular Research
  • Natural Product Chemistry

Background:

  • Genetic hypertension models, like Dahl salt-sensitive (DSS) rats, are crucial for studying cardiovascular diseases.
  • Insulin resistance is a common comorbidity in genetic hypertension, complicating treatment strategies.
  • Triterpenoids, such as oleanolic acid (OA) and ursolic acid (UA), are natural compounds with potential therapeutic benefits.

Purpose of the Study:

  • To investigate the cardiovascular, antihyperlipidemic, antioxidant, diuretic/saluretic, and hypoglycemic activities of oleanolic acid (OA) and ursolic acid (UA).
  • To evaluate the efficacy of OA and UA in preventing the development of severe hypertension in a rat model.

Main Methods:

  • Assessed the toxicity of OA and UA using LC50 measurements.
  • Administered daily doses of OA and UA (60 mg/kg b.w., i.p.) to Dahl salt-sensitive (DSS) rats for 6 weeks.
  • Monitored cardiovascular parameters (blood pressure, heart rate), lipid profiles, antioxidant enzyme activity (GPx, SOD), and blood glucose levels.

Main Results:

  • OA and UA demonstrated low toxicity (LC50 0.10 and 0.95 mg/ml).
  • Both compounds prevented severe hypertension development, attributed to diuretic, natriuretic, and saluretic effects.
  • Observed significant reductions in heart rate, LDL, triglycerides, and blood glucose, alongside increased antioxidant enzyme activity (GPx, SOD).

Conclusions:

  • Oleanolic acid and ursolic acid exhibit multifaceted pharmacological effects beneficial for managing hypertension.
  • The antihypertensive effects are linked to diuretic, cardiac, lipid-lowering, antioxidant, and hypoglycemic actions.
  • These findings represent novel in vivo antihypertensive effects of OA and UA, warranting further mechanistic investigation.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...